Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions

Citations Over TimeTop 10% of 2017 papers

Abstract

Hepatic organic cation transporter 1 (OCT1) can be a determinant of drug clearance and distribution, which can impact drug exposure and response. OCT1 was shown recently to be the rate-determining step in the clearance of several drugs in humans, and thereby a mechanism of pharmacogenetic variability and drug-drug interactions (DDIs). OCT1 mediates metformin distribution to the liver (key biophase). As OCT1 modulation impacts metformin response, but not pharmacokinetics (PK), metformin DDI studies require pharmacodynamic endpoint(s) to inform rational metformin dose adjustment.

Related Papers

• → Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action(2007)943 cited
• → A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes(2023)36 cited
• Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients.(2017)
• The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin(2015)
• → The relationship between OCT gene polymorphism and metformin therapeutic effects(2009)